We can’t show the full text here under this license. Use the link below to read it at the source.
Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta‐Analysis
Tirzepatide’s impact on pancreas safety and insulin-producing cell function: A combined review and analysis
AI simplified
Abstract
Analysis of 17 randomized controlled trials involving 14,645 subjects indicates that tirzepatide has similar pancreatitis risks compared to placebo.
- Tirzepatide did not show an increased risk of pancreatitis compared to placebo or other treatments like insulin and GLP-1 receptor agonists.
- All doses of tirzepatide led to greater increases in pancreatic amylase and lipase levels than placebo and insulin.
- Tirzepatide 10 and 15 mg resulted in greater reductions in fasting insulin levels compared to placebo.
- Tirzepatide produced larger percent reductions in fasting insulin, C-peptide, and glucagon levels than GLP-1 receptor agonists.
- Percent reductions in insulin resistance () were greater with all doses of tirzepatide compared to placebo and GLP-1 receptor agonists.
AI simplified
Key numbers
2.04
for (5 mg)
Risk of for 5 mg vs. placebo.
-37.0%
Percent Change in (15 mg)
Percent reduction in with 15 mg vs. placebo.
25.46%
Percent Change in (5 mg)
Percent increase in for 5 mg vs. placebo.